Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Very-Low-Level Viremia, Inflammatory Biomarkers, and Associated Baseline Variables: Three-Year Results of the Randomized TANGO Study.
Wang R, Underwood M, Llibre JM, Bernal Morell E, Brinson C, Sanz Moreno J, Scholten S, Moore R, Saggu P, Oyee J, Moodley R, Wynne B, Kisare M, Jones B, Ait-Khaled M. Wang R, et al. Among authors: oyee j. Open Forum Infect Dis. 2023 Dec 9;11(1):ofad626. doi: 10.1093/ofid/ofad626. eCollection 2024 Jan. Open Forum Infect Dis. 2023. PMID: 38213637 Free PMC article.
Durable Efficacy of Switching From a 3- or 4-Drug Tenofovir Alafenamide-Based Regimen to the 2-Drug Regimen Dolutegravir/Lamivudine in the TANGO Study Through Week 196.
De Wit S, Bonnet F, Osiyemi O, Bisshop F, Olalla J, Routy JP, Wyen C, Moodley R, Pappa K, Wang R, Oyee J, Saggu P, Letang E, Wynne B, Jones B, Smith KY, Ait-Khaled M. De Wit S, et al. Among authors: oyee j. J Acquir Immune Defic Syndr. 2024 Mar 1. doi: 10.1097/QAI.0000000000003395. Online ahead of print. J Acquir Immune Defic Syndr. 2024. PMID: 38346427
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based Regimen in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1: Subgroup Analysis of Participants With Elvitegravir as Baseline Third Agent From the TANGO Study.
Ait-Khaled M, Oyee J, Ooi AYR, Wynne B, Maldonado A, Jones B, Wang T. Ait-Khaled M, et al. Among authors: oyee j. Open Forum Infect Dis. 2024 May 2;11(5):ofae227. doi: 10.1093/ofid/ofae227. eCollection 2024 May. Open Forum Infect Dis. 2024. PMID: 38737429 Free PMC article. Clinical Trial.
Efficacy and safety of dolutegravir/lamivudine in virologically suppressed female participants: week 48 data from the pooled TANGO and SALSA studies.
Katlama C, Bisshop F, Bogner J, Pérez Elías MJ, Di Giambenedetto S, Clarke E, Hodder S, Nwokolo N, Ait-Khaled M, Oyee J, Grove R, Wynne B, Okoli C, Jones B, Kisare M. Katlama C, et al. Among authors: oyee j. HIV Med. 2024 Jul;25(7):873-884. doi: 10.1111/hiv.13643. Epub 2024 May 17. HIV Med. 2024. PMID: 38760011 Clinical Trial.
Patient-Reported Outcomes After Switching to a 2-Drug Regimen of Fixed-Dose Combination Dolutegravir/Lamivudine: 48-Week Results from the SALSA Study.
Kumar P, Clarke AE, Jonsson-Oldenbüttel C, Deltoro MG, Di Giambenedetto S, Brites C, Hocqueloux L, Lu PL, Oyee J, Oglesby A, Wynne B, Jones B, Evitt LA, Fox D, Kisare M, Priest J. Kumar P, et al. Among authors: oyee j. AIDS Behav. 2024 Sep 3. doi: 10.1007/s10461-024-04479-9. Online ahead of print. AIDS Behav. 2024. PMID: 39225890
Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial.
Llibre JM, Brites C, Cheng CY, Osiyemi O, Galera C, Hocqueloux L, Maggiolo F, Degen O, Taylor S, Blair E, Man C, Wynne B, Oyee J, Underwood M, Curtis L, Bontempo G, van Wyk J. Llibre JM, et al. Among authors: oyee j. Clin Infect Dis. 2023 Feb 18;76(4):720-729. doi: 10.1093/cid/ciac130. Clin Infect Dis. 2023. PMID: 35235656 Free PMC article. Clinical Trial.
Corrigendum: Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation.
Brown T, Pilkington G, Bagust A, Boland A, Oyee J, Tudur Smith C, Blundell M, Lai M, Martin Saborido C, Greenhalgh J, Dundar Y, Dickson R. Brown T, et al. Among authors: oyee j. Health Technol Assess. 2015 May;17(31):281-2. doi: 10.3310/hta17310-c201505. Health Technol Assess. 2015. PMID: 26061626 Free PMC article. No abstract available.
29 results